Enact Holdings (ACT) Q3 2026 Earnings Call Transcript

Enact reported Q3 adjusted operating income of $164 million, or $1.19 per diluted share, and raised 2026 capital-return guidance to approximately $600 million. Insurance in force was $275 billion, up 1% year over year, while persistency remained elevated at 81%; management cited favorable credit performance and a $37 million reserve release. New insurance written fell 7% sequentially to $14 billion as higher mortgage rates reduced refinance activity, and delinquencies rose seasonally; management expects delinquency rates could gradually increase into 2027 as newer books season.

Analysis

The key tension is durability versus replenishment: elevated persistency protects the in-force premium base when mortgage activity weakens, but a prolonged high-rate environment also constrains new business and slows portfolio refresh. That makes ACT’s near-term earnings less sensitive to originations than a headline NIW decline implies, while increasing the importance of seasoning performance in newer, purchase-heavy vintages.

Reported earnings quality is less robust than the capital-return message alone suggests. Reserve releases tied to cures are a meaningful support to current results; if cure performance normalizes as books season, earnings could soften even without a macro credit shock. Meanwhile, ceding more future production transfers tail risk and supports capital flexibility, but higher ceded premiums already pressure retained revenue. The 2028 agreement secures risk capacity, not necessarily attractive economics through a full cycle; verify treaty pricing and terms in filings.

The largest asymmetric catalyst is policy, not this quarter’s operating trend. Any FHFA/GSE pilot that accelerates mortgage-insurance cancellation could shorten premium duration and weaken the value of persistent policies, but the described initiative is prospective and key design details remain unresolved. In the next 1–3 months, track delinquency and cure trends, reserve development, and implementation guidance; over 6–18 months, watch whether newer vintages’ loss emergence remains within pricing assumptions. Rising rates also create AOCI volatility and potential book-value noise, though realized losses and reinvestment yields should be assessed together rather than treating AOCI as an immediate credit loss.

Contrarian view: capital returns may mask a slower-growth business. The signal is positive, but a policy-driven cancellation change or fading reserve releases could make buybacks less accretive than management’s confidence implies.

Key Decisions for Investors

• No chase on the earnings/capital-return headline alone. Consider ACT only on weakness if subsequent filings confirm stable vintage-level losses and cures; avoid treating reserve-release-supported EPS as a run rate.
• Set an alert for FHFA/GSE pilot details: cancellation eligibility, valuation method and buffers, effective dates, and who bears AVM costs. Reassess ACT if the framework materially accelerates cancellations or applies beyond prospective originations.
• Over the next two quarters, monitor delinquency roll rates, cure rates, claim rates, and reserve releases together. A sustained deterioration in cures or losses above management’s vintage expectations would falsify the resilient-credit thesis and argue against adding exposure.
• Track net earned premium rate and reinsurance economics alongside new business. If ceded costs continue to erode retained premiums without a corresponding improvement in capital flexibility, the 2028 risk-transfer agreement may be less shareholder-accretive than the headline suggests.